Treatment of recalcitrant atopic dermatitis with omalizumab

Joshua E Lane; Jason M Cheyney; Tanda N Lane; David E Kent; David J Cohen

doi:10.1016/j.jaad.2005.09.030

Treatment of recalcitrant atopic dermatitis with omalizumab

J Am Acad Dermatol. 2006 Jan;54(1):68-72. doi: 10.1016/j.jaad.2005.09.030. Epub 2005 Nov 28.

Authors

Joshua E Lane¹, Jason M Cheyney, Tanda N Lane, David E Kent, David J Cohen

Affiliation

¹ Division of Dermatology, Department of Internal Medicine, Mercer University School of Medicine, Macon, Georgia 31217, USA. joshua.lane@lycos.com

PMID: 16384758
DOI: 10.1016/j.jaad.2005.09.030

Abstract

Atopic dermatitis is a common diagnosis that presents a therapeutic challenge. Although multiple therapeutic modalities exist, there is no single monotherapy that has proven exceptional in ameliorating the symptoms of this disease. Current topical and systemic therapeutic options offer benefit but carry varying degrees of adverse effects that often limit their application. We present 3 patients with severe, recalcitrant atopic dermatitis successfully treated with omalizumab.

Publication types

Case Reports

MeSH terms

Antibodies, Anti-Idiotypic
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Child
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / pathology
Dose-Response Relationship, Drug
Drug Resistance
Drug Therapy, Combination
Female
Humans
Injections, Subcutaneous
Omalizumab
Treatment Outcome

Substances

Antibodies, Anti-Idiotypic
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Omalizumab